Mesenchymal stromal cells (MSCs) are multipotent progenitor cells capable of differentiating into adipocytes, osteoblasts and chondroblasts as well as secreting a vast array of soluble mediators. This potentially makes MSCs important mediators of a variety of therapeutic applications. They are actively under evaluation for immunomodulatory purposes such as graft-versus-host disease and Crohn's disease as well as regenerative applications such as stroke and congestive heart failure. We report our method of generating clinical-grade MSCs together with suggestions gathered from manufacturing experience in our Good Manufacturing Practices facility.
Manufacturing mesenchymal stromal cells for phase I clinical trials.
生产用于 I 期临床试验的间充质干细胞
阅读:4
作者:Hanley Patrick J, Mei Zhuyong, da Graca Cabreira-Hansen Maria, Klis Mariola, Li Wei, Zhao Yali, Durett April G, Zheng Xingwu, Wang Yongping, Gee Adrian P, Horwitz Edwin M
| 期刊: | Cytotherapy | 影响因子: | 3.200 |
| 时间: | 2013 | 起止号: | 2013 Apr;15(4):416-22 |
| doi: | 10.1016/j.jcyt.2012.09.007 | 研究方向: | 发育与干细胞、细胞生物学 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
